腹腔恶性肿瘤预后不良。对于无法手术的腹腔疾病患者，全身化疗是治疗的金标准，但其腹腔内效果受到腹腔－血浆屏障的阻碍。经腹腔成植入口反复给予的腹腔内化疗可为该患者群提供一种新的治疗方式。本文系统概述了腹腔内用药、迄今为止进行的临床研究以及腹腔成植入口的并发症。多种抗癌药物已被研究用于腹腔内应用，紫杉醇和多西他赛是最常用的药物。重复给予腹腔内化疗，大多与全身化疗联合使用，已在多种肿瘤类型中显示出相当的前景，如胃癌、卵巢癌、结肠直肠癌和胰腺癌。迄今为止，已开展了两项胃癌腹腔内化疗的III期研究，但其是否优于标准全身化疗仍然存在争议。加压腹腔内给药（PIPAC）是给予腹腔内化疗的另一种方法，第一批前瞻性研究表明其安全性良好。虽然腹腔内化疗可能成为无法切除的腹腔疾病患者的一种标准治疗选择，但仍需要更多以耐受性、生存率和生活质量为重点的II期和III期研究，以建立最佳治疗方案并确定腹腔内化疗在无法手术的腹腔疾病治疗中的潜在作用。 © 2023. The Author(s)。

Malignancies of the peritoneal cavity are associated with a dismal prognosis. Systemic chemotherapy is the gold standard for patients with unresectable peritoneal disease, but its intraperitoneal effect is hampered by the peritoneal-plasma barrier. Intraperitoneal chemotherapy, which is administered repeatedly into the peritoneal cavity through a peritoneal implanted port, could provide a novel treatment modality for this patient population. This review provides a systematic overview of intraperitoneal used drugs, the performed clinical studies so far, and the complications of the peritoneal implemental ports. Several anticancer drugs have been studied for intraperitoneal application, with the taxanes paclitaxel and docetaxel as the most commonly used drug. Repeated intraperitoneal chemotherapy, mostly in combination with systemic chemotherapy, has shown promising results in Phase I and Phase II studies for several tumor types, such as gastric cancer, ovarian cancer, colorectal cancer, and pancreatic cancer. Two Phase III studies for intraperitoneal chemotherapy in gastric cancer have been performed so far, but the results regarding the superiority over standard systemic chemotherapy alone, are contradictory. Pressurized intraperitoneal administration, known as PIPAC, is an alternative way of administering intraperitoneal chemotherapy, and the first prospective studies have shown a tolerable safety profile. Although intraperitoneal chemotherapy might be a standard treatment option for patients with unresectable peritoneal disease, more Phase II and Phase III studies focusing on tolerability profiles, survival rates, and quality of life are warranted in order to establish optimal treatment schedules and to establish a potential role for intraperitoneal chemotherapy in the approach to unresectable peritoneal disease.© 2023. The Author(s).